

The promises of Treg and Interleukin-2 therapies for autoimmune and inflammatory diseases, allergy, transplantation and cancer



**Centre International de Conférences Sorbonne Université
October 21-24, 2026**

International Organizing Committee

Abul Abbas, Christophe Benoist, Jeff Bluestone, Laurie Dempsey, David Klatzmann (Chair),
Thomas Malek, Qizhi Tang, Shimon Sakaguchi, Georges Tsokos, Lucy Walker

Local Organizing Committee

Caroline Aheng, Encarnita Mariotti-Ferrandiz, Michelle Rosenzweig, Nicolas Tchitchek

Current list of confirmed invited speakers

Abul Abbas; Ammar Al Chalabi; Christof Binder; Marina Cavazzana; Jens Humrich; Ron Germain;
Wolfgang Kastenmueller; David Klatzmann; Vijay Kuchroo; Zhanguo Li; Wan-Lin Lo; Ziad Mallat; T
Malek; Adel Nada; Asia Rolls; Sacha Rudensky; Naomi Taylor; George Tsokos; Serena Zacchigna;
Jonathan Zalevsky; David Zemmour

Platinum sponsor



Gold sponsor

Bronze sponsor

Partners



Wednesday 21

18.00 - Opening Session

Welcome words: **Abul Abbas**

Keynote lectures

Chair: **Abul Abbas**

- *Treg 2026* – Alexander Rudensky
- *IL-2 based therapies 2026* – David Klatzmann

20.00 - Welcome reception

Thursday 22

9.00 Session I - *On mechanistic: Treg development and heterogeneity*

Chair: Lucie Walker

1. David Zemmour: Treg Cosmology in the immgenT datasets
2. Wan-Lin Lo: in search of the lost Zap70 signal

Talks from abstracts

- a.
- b.

10.30 – 11.00 – Coffee break

11.00 Session II – *Lessons successes from clinical trials with native IL-2*

Chair: George Tsokos

3. Zhanguo Li: IL-2 in China: from trial to market approval (20)
4. Ammar Al Chalabi: IL-2 in Amyotrophic Lateral Sclerosis (20)
5. Johnatan Zalevski: Pegylated native IL-2 (20)

Talks from abstracts

- c.
- d.

13.00 – 14.00 – Lunch

14.00 Session III - *On mechanistic: Treg activation and metabolism*

Chair: Christophe Benoist

6. T Malek: Co-targeting the CD40L pathway potentiates Treg-selective IL-2-driven therapy
7. Wolfgang Kastenmueller : TBA
8. George Tsokos: Treg cell metabolism in SLE

Talks from abstracts

- e.
- f.

16.00 – 16.30 – Coffee break

16.30 Session IV – *CNS and the control of inflammation (and vice versa)*

Chair: Laurie Dempsey

9. Asia Roll : Immunoception: defining brain-regulated immunity
10. Vijay Kuchroo: TBA

Talks from abstracts

- g.
- h.

18.30 End of the day

20.00 speaker dinner

Friday 23

9.00 Session V – *IL-2 in cardiovascular diseases (sponsored session by TiILT EU research grant)*

Chair: Mauro Giacca

11. Ziad Mallat: IL-2 and atherosclerosis
12. Christof Binder: on Treg, OSE and inflammatory CVD
13. Thomas Vazquez: OSE-targeted IL-2
14. Serena Zacchigna: IL-2 and cardiac infarction recovery
15. Jens Humrich: IL-2 and cardio-vascular SLE

11.00 – 11.30 – Coffee break

11.00 - Session VI - *Treg cell therapies*

Chair: Qizi Tang

16. Naomi Taylor: Engineering TCR fuzzy logic in CAR T cells: implication for CAR-Tregs TBA
17. TBA

Talks from abstracts

- a.
- b.

13.00 - 14.00 – Lunch

14.00 - Session VII – *on Treg antigen specificities*

Chair: Encarnita Mariotti-Ferrandiz

18. Ron Germain: TBA
19. Christoph Benoist: TBA

Talks from abstracts

- a.
- b.

15.30 - 16.00 – Coffee break

16.00 - Session VII – *Lessons from IL-2 and CAR T cell in cancer therapy*

Chair: TBD

1. Alfred Zipelius: PD-1–targeted cis-delivery of an IL-2 variant induces a multifaceted antitumoral T cell response in human lung cancer
2. TBA

Talks from abstracts

- c.
- d.

18.00 Drinks and posters

19.30 End of the day

Saturday 24

9.00 Session VIII- *IL-2 and Treg cell therapies*

Chair: David Klatzmann

1. TBA
2. Marina Cavazzana-Calvo: FoxP3-transduced CD4 T cells for IPEX

Talks from abstracts

- e.
- f.

10.30 – 11.00 – Coffee break 11.30

11.00 Session IX – *IL-2 and Tregs: the pharma perspective*

Chair: Abul Abbas

3. Jonathan Zalevsky/Nektar: Pegylated IL-2
4. William Hariri/ILTOO: IL-2 in neuroinflammatory diseases
5. Adel Nada/Trutina: The future of Treg cell therapies
6. Round Table: What 's next?

12.30 End of the meeting